TYRATECH, INC. • ANNUAL REPORT 2011 • PAGE 17
joined the Bowater Organization, where he had responsibility
for the finance function at several operations. From there
he moved to FMC Corporation, the U.S. conglomerate where
he had finance and general management responsibilities for
a specialty chemical operation, and also oversaw the head
office finance function for all UK operations. He joined Proteus
International plc in 1995 as Finance Director and was closely
involved in the merger with Therapeutic Antibodies Inc. in
1999, which became Protherics Plc where he was Finance Director
until 2007. He is chairman of the Audit Committee and
a member of the Nomination Committee.
James Hills (Non-executive Director) was appointed on July 9,
2010. Mr. Hills spent the early portion of his career with The
Gillette Company and Coca Cola USA where he held senior
positions in both sales and brand management. Later, he was
a 50% partner and Chief Executive Officer of Weatherly Consumer
Products Inc., a company which developed, branded
and marketed specialty fertilizers in North America and Europe,
under the Jobe's brand name. Following the sale of that
business in 1996, he started Gulfstream Home and Garden, a
company which marketed lawn and garden insecticides under
the Sevin brand name in the U.S. He sold that business
in 2005 following nearly ten years of rapid growth. Mr. Hills is
chairman of the Remuneration Committee and a member of
the Audit Committee.
Kevin T. Schultz, D.V.M., Ph.D. (Non-executive Director) was
appointed to the board on April 1, 2012. Dr. Schultz served
as TyraTech's Chief Scientific Officer from August 2010 through
March 2012. Dr. Schultz began his corporate work as Executive
Director, World-Wide Animal Science Research & Development
at Merck. He was one of the founding executives to
combine the Animal Health Division of Merck with Rhone Merieux
and was subsequently appointed Head of Pharmaceutical
Research and Development. Following that, Dr. Schultz
assumed the role of Chief Scientific Officer and Global Head
of all Research and Development for Merial (pharmaceutical
and biological). Dr. Schultz received his Doctor of Veterinary
Medicine from Purdue University and earned a Ph.D. from the
University of Florida Medical School before joining Harvard
Medical School and Harvard School of Public Health as a Fellow
in Cancer Biology. He was a Professor in the Department of
Pathobiological Sciences at the University of Wisconsin-Madison
and had his own private veterinary practice. Dr. Schultz
has published more than 50 peer-reviewed papers and contributed
to more than 20 books and compendiums. He is also
a Venture Fellow with the Georgia Research Alliance.
DIRECTORS' INTERESTS
The directors at June 1, 2012 and their beneficial interests in
the share capital of the Group, other than with respect to
options to acquire ordinary shares (which are detailed in the
analysis of options included in the Directors' Remuneration
Report) are as follows:
1 June, 2012 1 January, 2011
(or earlier date (or later date
of resignation) of appointment)
Common Shares Common Shares
of US$0.001 each of US$0.001 each
A.J. Reade 7,561,358 4,071,808
B.M. Riley 2,255,556 1,255,556
P. Regan (resigned May 31, 2011) 566,674 566,674
J. Hills 365,500 Nil
